Literature DB >> 28924047

Endothelial Rab7 GTPase mediates tumor growth and metastasis in lysosomal acid lipase-deficient mice.

Ting Zhao1, Xinchun Ding1, Cong Yan2,3, Hong Du4,3.   

Abstract

Tumors depend on their microenvironment for sustained growth, invasion, and metastasis. In this environment, endothelial cells (ECs) are an important stromal cell type interacting with malignant cells to facilitate tumor angiogenesis and cancer cell extravasation. Of note, lysosomal acid lipase (LAL) deficiency facilitates melanoma growth and metastasis. ECs from LAL-deficient (lal-/-) mice possess enhanced proliferation, migration, and permeability of inflammatory cells by activating the mammalian target of rapamycin (mTOR) pathway. Here we report that lal-/- ECs facilitated in vivo tumor angiogenesis, growth, and metastasis, largely by stimulating tumor cell proliferation, migration, adhesion, and transendothelial migration via increased expression of IL-6 and monocyte chemoattractant protein 1 (MCP-1). This prompted us to look for lysosomal proteins that are involved in lal-/- EC dysfunctions. We found that lal-/- ECs displayed increased expression of Rab7, a late endosome/lysosome-associated small GTPase. Moreover, Rab7 and mTOR were co-increased and co-localized to lysosomes and physically interacted in lal-/- ECs. Rab7 inhibition reversed lal-/- EC dysfunctions, including decreasing their enhanced migration and permeability of tumor-stimulatory myeloid cells, and suppressed EC-mediated stimulation of in vitro tumor cell transmigration, proliferation, and migration and in vivo tumor growth and metastasis. Finally, Rab7 inhibition reduced overproduction of reactive oxygen species and increased IL-6 and MCP-1 secretion in lal-/- ECs. Our results indicate that metabolic reprogramming resulting from LAL deficiency enhances the ability of ECs to stimulate tumor cell proliferation and metastasis through stimulation of lysosome-anchored Rab7 activity.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Rab7 GTPase; cancer therapy; endothelial cell; lysosomal acid lipase; lysosome; tumor metastasis; tumor microenvironment

Mesh:

Substances:

Year:  2017        PMID: 28924047      PMCID: PMC5702662          DOI: 10.1074/jbc.M116.773093

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling.

Authors:  Qinghua Zeng; Shenglin Li; Douglas B Chepeha; Thomas J Giordano; Jong Li; Honglai Zhang; Peter J Polverini; Jacques Nor; Jan Kitajewski; Cun-Yu Wang
Journal:  Cancer Cell       Date:  2005-07       Impact factor: 31.743

Review 2.  Crossing the endothelial barrier during metastasis.

Authors:  Nicolas Reymond; Bárbara Borda d'Água; Anne J Ridley
Journal:  Nat Rev Cancer       Date:  2013-12       Impact factor: 60.716

Review 3.  Endocytic Rabs in membrane trafficking and signaling.

Authors:  Johannes Numrich; Christian Ungermann
Journal:  Biol Chem       Date:  2014-03       Impact factor: 3.915

Review 4.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

Review 5.  Endothelial cells in the eyes of an immunologist.

Authors:  M Rita Young
Journal:  Cancer Immunol Immunother       Date:  2012-08-18       Impact factor: 6.968

Review 6.  Rab7: roles in membrane trafficking and disease.

Authors:  Ming Zhang; Li Chen; Shicong Wang; Tuanlao Wang
Journal:  Biosci Rep       Date:  2009-06       Impact factor: 3.840

7.  Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.

Authors:  Maikel A Farhan; Katia Carmine-Simmen; John D Lewis; Ronald B Moore; Allan G Murray
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

8.  Lymphatic endothelial cells support tumor growth in breast cancer.

Authors:  Esak Lee; Niranjan B Pandey; Aleksander S Popel
Journal:  Sci Rep       Date:  2014-07-28       Impact factor: 4.379

9.  Rab7 GTPase controls lipid metabolic signaling in myeloid-derived suppressor cells.

Authors:  Xinchun Ding; Wenjing Zhang; Ting Zhao; Cong Yan; Hong Du
Journal:  Oncotarget       Date:  2017-05-02

10.  Activation of mTOR pathway in myeloid-derived suppressor cells stimulates cancer cell proliferation and metastasis in lal(-/-) mice.

Authors:  T Zhao; H Du; X Ding; K Walls; C Yan
Journal:  Oncogene       Date:  2014-06-02       Impact factor: 9.867

View more
  5 in total

Review 1.  Connecting Cholesterol Efflux Factors to Lung Cancer Biology and Therapeutics.

Authors:  Maria Maslyanko; Ryan D Harris; David Mu
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

2.  Rab7 Is Associated with Poor Prognosis of Gastric Cancer and Promotes Proliferation, Invasion, and Migration of Gastric Cancer Cells.

Authors:  Huiyong Liu; Jie Xu; Qingzhi Yao; Zhongyi Zhang; Qiaonan Guo; Jianqing Lin
Journal:  Med Sci Monit       Date:  2020-06-27

Review 3.  Tumor-derived exosomes (TDEs): How to avoid the sting in the tail.

Authors:  MeiHua Wan; Bo Ning; Sarah Spiegel; Christopher J Lyon; Tony Y Hu
Journal:  Med Res Rev       Date:  2019-07-18       Impact factor: 12.944

Review 4.  Linking Late Endosomal Cholesterol with Cancer Progression and Anticancer Drug Resistance.

Authors:  Mai K L Nguyen; Jaimy Jose; Mohamed Wahba; Marc Bernaus-Esqué; Andrew J Hoy; Carlos Enrich; Carles Rentero; Thomas Grewal
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

5.  15-Year progression to liver cancer in the lack of treatment for lysosomal acid lipase deficiency: A case report.

Authors:  Marlone Cunha-Silva; Eloy Vianey Carvalho de França; Clauber Teles Veiga; Raquel Dias Greca; Priscilla Brito Sena de Moraes; Daniel Ferraz de Campos Mazo; Elaine Cristina de Ataíde; Simone Reges Perales; Leonardo Trevizan Monici; Tiago Sevá-Pereira
Journal:  Medicine (Baltimore)       Date:  2022-09-02       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.